Together with previous studies demonstrating a renoprotective effect of CT‐1 in the context of acute (Garcia‐Cenador et al., 2013, 2018; Quiros et al., 2013, 2016) and chronic (Perretta‐Tejedor et al., 2019) kidney injury, CT‐1 is emerging as a promising therapeutic target in kidney disease. Here, CTF1 is linked to kidney disorder.